Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$146.58+2.23 (+1.54%)
Close on Nov 18, 2026Market cap $2.11BP/E –Yield –
Palvella Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Palvella Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$57.74M. For fiscal 2025 it was -$38.60M. The highest annual figure on record is $553.83K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.60M | – |
| FY2024 | Dec 31, 2024 | -$14.10M | – |
| FY2023 | Dec 31, 2023 | -$11.87M | – |
| FY2022 | Dec 31, 2022 | -$43.47M | – |
| FY2021 | Dec 31, 2021 | -$51.83M | – |
| FY2020 | Dec 31, 2020 | -$33.92M | – |
| FY2019 | Dec 31, 2019 | -$27.16M | – |
| FY2018 | Dec 31, 2018 | -$30.83M | – |
| FY2017 | Dec 31, 2017 | -$14.59M | – |
| FY2016 | Dec 31, 2016 | -$22.76M | – |
| FY2015 | Dec 31, 2015 | -$13.68M | – |
| FY2014 | Dec 31, 2014 | -$7.20M | -1399.7% |
| FY2013 | Dec 31, 2013 | $553.83K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.37M | -132.6% |
| Q3 FY2024 | Sep 30, 2024 | -$5.06M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.91M | -241.0% |
| Q1 FY2024 | Mar 31, 2024 | -$1.76M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.81M | – |
| Q2 FY2023 | Jun 30, 2023 | $2.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.00M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.65M | -294.9% |
| Q3 FY2018 | Sep 30, 2018 | -$7.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.14M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.49M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.01M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.40M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.18M | – |
See a number that looks wrong?